Respiratory diseases caused by viral agents are one of the most critical problems in public health, as every year they are responsible for high rates of morbidity and mortality, mainly of young children, the elderly and immunocompromised individuals [1-3]. Viral respiratory pathogens have come to the fore as a major cause for pandemics and therefore a better understanding of their disease spectrum is of great public health significance [4, 5].
They don't stop coming—patients in Italy with respiratory problems that make it so hard to catch a breath that they brave the streets in this city in the Lombardia region to get to the emergency room at University of Brescia. This is no time for patients with chronic diseases in Italy, who are often told to stay home.
Advances in treatment of Spinal Muscular Atrophy (SMA) has been topical for a number of years. As new treatment options continue to gain FDA approval, the “snowball effect” continues to bring new insights into SMA management. Changing phenotypes, need for earlier patient identification and carrier testing, additional treatment avenues and the shifting of more attention to the non-neuromuscular aspects of SMA and quality of life were in the past, overwhelmingly overshadowed by the devastating neuromuscular consequences of SMA. The 4 articles that we have selected address some of these issues.